2024-515442-17-00招募中1 期
Evaluation of safety, side effects and how the inhaled drug CHF10073 is absorbed, modified and removed from the body when administered alone or in combination with itraconazole in male and female healthy adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 132
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
GLOBAL CLINICAL DEVELOPMENT
Scientific
Chiesi Farmaceutici S.p.A.
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Evaluate the safety, side effects and maximum tolerable dose of 5 Antimicrobial Peptides on the skin of healthy volunteers to the treatment of Skin and Soft Tissue Infections.IRCT20190924044863N1Mashhad University of Medical Sciences30
已完成
不适用
The evaluation of the clinical effect and safety of stereotactic body radiationtherapy for hepatocellularcarcinomaJPRN-UMIN000016834Hiroshima university100
招募中
不适用
Safety evaluation and therapeutic effect analysis of knee hyperthermia with resonant cavity applicatorJPRN-UMIN000033721nternational University of Health and Welfare20
已完成
不适用
Clinical Evaluation of the Safety and Effectiveness of Harvest Autologous Platelet Concentrate and Harvest Autologous Thrombin for Treatment of Lower Extremity Chronic Diabetic UlcersISRCTN28965380Harvest Technologies Corp. (USA)59
进行中（未招募）
1 期
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12